Professor Mark Rosenthal
MBBS FRACP PhD
VCCC Clinical Trials Development Lead
Director, Parkville Cancer Clinical Trials Unit, Medical Oncologist
View alliance profile
Clinical trials expansion is a major focus of the VCCC’s ongoing work program, as well as a distinct portfolio highlighted in the Strategic Research Plan 2017-20 with a goal to deliver, ‘more clinical trials covering more cancer disciplines, and more patients getting the opportunity to participate in trials and clinical research’.
Professor Mark Rosenthal provides leadership to the clinical trials portfolio, capitalising on the members’ size, scale and scope to boost innovative clinical trials capability and capacity.
In Victoria, 70 per cent of all cancer clinical trials are conducted at either Western Health, Royal Children’s Hospital, Royal Women’s Hospital, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, St Vincent’s Hospital or Austin Health. VCCC alliance members provide a critical mass of successful clinical trial facilities and clinician researchers, with proven infrastructure and established governance methods.
Working closely with Anne Woollett, Head of Clinical Trial Programs and her team, Professor Rosenthal provides strategic direction and advice to drive a cohesive multi-pronged approach to deliver an expanded clinical trial portfolio.
Professor Rosenthal trained as a medical oncologist in Melbourne and Sydney. He was awarded a PhD at the Ludwig Institute for Cancer Research and completed post-graduate training at the New York University Medical Centre. Professor Rosenthal is a medical oncologist at Peter Mac and Director of the Parkville Cancer Clinical Trials Unit. He has previously held roles at the Royal Melbourne Hospital, and was Chairman and Chief Medical Officer of Cancer Trials Australia. He was the inaugural Chairman of the Cooperative Trials Group for Neuro-Oncology (COGNO).